We are advancing a pipeline of novel therapeutics for epilepsies, autism, and other CNS disorders.

science

Pushing the boundaries of neuroscience drug discovery


We couple emerging advances in neuroscience drug discovery and precision medicine for neuroscience to advance our pipeline of small molecule therapies for CNS disorders. Our therapies are designed to selectively inhibit clinically validated therapeutic targets and restore neuronal balance.

 

team

Working at IAMA therapeutics



We are a team of scientists, researchers, and biotech industry experts who value excellence, innovation, integrity, equality, respect for diversity, and the sustainability of our future generations.

latest news

1 December 2023

IAMA Therapeutics to Present New Preclinical Data at Upcoming American Epilepsy Society 2023 Annual Meeting

Study results support the potential for IAMA-6 as a disease-modifying therapy for drug-resistant epilepsies GENOA, Italy, December 1, 2023 — IAMA Therapeutics, a pharmaceutical company focused […]
2 October 2023

IAMA Therapeutics Announces Multi-Phase, Strategic Provider Agreement with Evotec

GENOA, Italy, October 02, 2023 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain […]
13 September 2023

IAMA Therapeutics to Present at Sachs Associates 23rd Annual Biotech in Europe Forum

GENOA, Italy, September 13, 2023 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain […]